Skip to main content
SpringerLink
Log in

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma

  • Clinical study - patient study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age = 56.8 years; median KPS = 90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Legler JM, Ries LA, Smith MA et al (1999) Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91:1382–1390. doi:10.1093/jnci/91.16.1382

    Article  PubMed  CAS  Google Scholar 

  2. Levin VA, Leibel SA, Gutin PH (2001) Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott Williams & Wilkins, Philadelphia, Pa, pp 2100–2160

    Google Scholar 

  3. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330

    Article  PubMed  CAS  Google Scholar 

  4. DeAngelis LM (2005) Chemotherapy for brain tumors—a new beginning. N Engl J Med 352(10):1036–1038. doi:10.1056/NEJMe058010

    Article  PubMed  CAS  Google Scholar 

  5. Taphoorn MJ, Stupp R, Coens C et al (2005) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6(12):937–944. doi:10.1016/S1470-2045(05)70432-0

    Article  PubMed  Google Scholar 

  6. Keles GE, Anderson B, Berger MS (1999) The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52:371–379. doi:10.1016/S0090-3019(99)00103-2

    Article  PubMed  CAS  Google Scholar 

  7. Kowalczuk A, Macdonald RL, Amidei C et al (1997) Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41:1028–1038. doi:10.1097/00006123-199711000-00004

    Article  PubMed  CAS  Google Scholar 

  8. Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extentof resection, and survival. J Neurosurg 95:190–198

    Article  PubMed  CAS  Google Scholar 

  9. Stupp R, Mason WP, Van Den Bent MJ, et al (2004) Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain and RT Groups and NCIC Clinical Trials Group [Abstract]. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol 22, No 14S (July 15 Supplement) 2

  10. Nieder C, Adam M, Molls M et al (2006) Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60(3):181–193. doi:10.1016/j.critrevonc.2006.06.007

    Article  PubMed  Google Scholar 

  11. Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008–1012. doi:10.1016/S0140-6736(95)90755-6

    Article  PubMed  CAS  Google Scholar 

  12. Pinsker M, Lumenta C (2001) Experience with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir 62:43–47. doi:10.1055/s-2002-19477

    Article  PubMed  CAS  Google Scholar 

  13. Olivi A, Grossman SA, Tatter S et al (2003) Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 21:1845–1849. doi:10.1200/JCO.2003.09.041

    Article  PubMed  CAS  Google Scholar 

  14. Franceschi E, Omuro AM, Lassman AB et al (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104(11):2473–2476. doi:10.1002/cncr.21564

    Article  PubMed  CAS  Google Scholar 

  15. Kong DS, Lee JI, Kim WS et al (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16(5):1117–1121

    PubMed  CAS  Google Scholar 

  16. Chamberlain MC, Tsao-Wei DD (2004) Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 15, 100(6):1213–1220

    Article  CAS  Google Scholar 

  17. Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22(23):4779–4786. doi:10.1200/JCO.2004.06.181 Erratum in: J Clin Oncol 2005 23. 1:248

    Article  PubMed  CAS  Google Scholar 

  18. Fine HA, Wen PY, Maher EA et al (2003) Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21(12):2299–2304. doi:10.1200/JCO.2003.08.045

    Article  PubMed  CAS  Google Scholar 

  19. Kayat D, Lokiec F, Bizzarri JP et al (1987) Phase I clinical study of the new amino acid-linked nirtrosourea, S 10036, administered in a weekly schedule. Cancer Res 47:6782–6785

    Google Scholar 

  20. Kleeberg UR, Engel E, Israels P et al (1995) Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 5(3):195–200. doi:10.1097/00008390-199506000-00009

    Article  PubMed  CAS  Google Scholar 

  21. Silvani A, Lamperti E, Gaviani P et al (2008) Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 87(2):143–151. doi:10.1007/s11060-007-9427-y

    Article  PubMed  CAS  Google Scholar 

  22. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216. doi:10.1093/jnci/92.3.205

    Article  PubMed  CAS  Google Scholar 

  23. Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    PubMed  CAS  Google Scholar 

  24. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481. doi:10.2307/2281868

    Article  Google Scholar 

  25. Curran WJ, Scott JB, Horton JS et al (1993) Recursive partition analysis of prognostic factors in three radiation therapy and oncology group malignant glioma trials. J Natl Cancer Inst 85:704–710. doi:10.1093/jnci/85.9.704

    Article  PubMed  Google Scholar 

  26. Lai A, Filka E, McGibbon B et al (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71(5):1372–1380. doi:10.1016/j.ijrobp.2007.11.068

    PubMed  CAS  Google Scholar 

  27. Ali SA, McHayleh WM, Ahmad A et al (2008) Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg 109(2):268–272. doi:10.3171/JNS/2008/109/8/0268

    Article  PubMed  CAS  Google Scholar 

  28. Bokstein F, Shpigel S, Blumenthal DT (2008) Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112(10):2267–2273. doi:10.1002/cncr.23401

    Article  PubMed  CAS  Google Scholar 

  29. Norden AD, Young GS, Setayesh K (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10):779–787. doi:10.1212/01.wnl.0000304121.57857.38

    Article  PubMed  CAS  Google Scholar 

  30. Fazeny-Dorner B et al (2003) Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs 14:437–442. doi:10.1097/00001813-200307000-00008

    Article  PubMed  Google Scholar 

  31. Frenay M, Giroux B, Khoury S et al (1991) Phase II study of fotemustine in recurrent sopratentorial malignant gliomas. Eur J Cancer 27(7):852–856

    PubMed  CAS  Google Scholar 

  32. Scoccianti S, Detti B, Iannalfi A et al (2008) Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institutional experience. Anti-Cancer Drug 19:6613–6620

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiotherapy Division of Pisa University Hospital, Pisa, Italy

    Maria Grazia Fabrini, Valerio Scotti & Luca Cionini

  2. Azienda Ospedaliero-Universitaria Pisana, U.O. Radioterapia, via Roma, 67, Pisa, 56127, Italy

    Maria Grazia Fabrini

  3. Radiotherapy Division of “SS. Annunziata” Taranto Hospital, Taranto, Italy

    Giovanni Silvano & Annarita Marsella

  4. Oncology Division of Bari University Clinic, Bari, Italy

    Ivan Lolli

  5. Health Physics Division of Pisa University Hospital, Pisa, Italy

    Franco Perrone

Authors
  1. Maria Grazia Fabrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni Silvano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ivan Lolli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Franco Perrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Annarita Marsella
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Valerio Scotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luca Cionini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Grazia Fabrini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fabrini, M.G., Silvano, G., Lolli, I. et al. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92, 79–86 (2009). https://doi.org/10.1007/s11060-008-9739-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-008-9739-6

Keywords

Search

Navigation